Moderna is seeking full approval for the mFlusiva vaccine, with Vinay Prasad disputing the initial review under Health Secretary scrutiny.
7 reports, 6 independent
Updated Aug 6
Gone quiet
Reached 5 outlets in its first 24 hours
- Reports
- 7
- Developments
- 4
- Repetition
- 57%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna is seeking full approval for the mFlusiva vaccine, with Vinay Prasad disputing the initial review under Health Secretary scrutiny.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Moderna is seeking approval for its mRNA flu vaccine and targeting the US market for its products.Sub-event
Moderna seeks full approval for mFlusiva vaccine amid review disputes.1 source
FDA is evaluating Moderna's messenger RNA-based flu shot.1 source
Moderna is seeking FDA approval for its mRNA-1010 vaccine.1 source